|
1
|
Eichelser C, Flesch-Janys D, Chang-Claude
J, Pantel K and Schwarzenbach H: Deregulated serum concentrations
of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and
miR-373 in human breast cancer development and progression. Clin
Chem. 59:1489–1496. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wei C, Cao Y, Yang X, Zheng Z, Guan K,
Wang Q, Tai Y, Zhang Y, Ma S, Cao Y, et al: Elevated expression of
TANK-binding kinase 1 enhances tamoxifen resistance in breast
cancer. Proc Natl Acad Sci USA. 111:E601–E610. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fan L, Strasser-Weippl K, Li JJ, St Louis
J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast
cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li J, Zhang BN, Fan JH, Pang Y, Zhang P,
Wang SL, Zheng S, Zhang B, Yang HJ, Xie XM, et al: A nation-wide
multicenter 10-year (1999–2008) retrospective clinical
epidemiological study of female breast cancer in China. BMC cancer.
11:3642011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Loi S, Sirtaine N, Piette F, Salgado R,
Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al:
Prognostic and predictive value of tumor-infiltrating lymphocytes
in a phase III randomized adjuvant breast cancer trial in
node-positive breast cancer comparing the addition of docetaxel to
doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin
Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Molina R, Auge JM, Farrus B, Zanón G,
Pahisa J, Muñoz M, Torne A, Filella X, Escudero JM, Fernandez P and
Velasco M: Prospective evaluation of carcinoembryonic antigen (CEA)
and carbohydrate antigen 15.3 (CA 15.3) in patients with primary
locoregional breast cancer. Clin Chem. 56:1148–1157. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arslan C, Aksoy S, Dizdar O, Kurt M, Güler
N, Ozisik Y, Güllü I and Altundag K: Increased mean corpuscular
volume of erythrocytes during capecitabine treatment: A simple
surrogate marker for clinical response. Tumori. 97:711–716.
2011.PubMed/NCBI
|
|
10
|
Azab B, Bhatt VR, Phookan J, Murukutla S,
Kohn N, Terjanian T and Widmann WD: Usefulness of the
neutrophil-to-lymphocyte ratio in predicting short- and long-term
mortality in breast cancer patients. Ann Surg Oncol. 19:217–224.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nakano K, Hosoda M, Yamamoto M and
Yamashita H: Prognostic significance of pre-treatment neutrophil:
Lymphocyte ratio in Japanese patients with breast cancer.
Anticancer Res. 34:3819–3824. 2014.PubMed/NCBI
|
|
12
|
Ishizuka M, Nagata H, Takagi K, Iwasaki Y
and Kubota K: Combination of platelet count and neutrophil to
lymphocyte ratio is a useful predictor of postoperative survival in
patients with colorectal cancer. Br J Cancer. 109:401–407. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dirican A, Kucukzeybek BB, Alacacioglu A,
Kucukzeybek Y, Erten C, Varol U, Somali I, Demir L, Bayoglu IV,
Yildiz Y, et al: Do the derived neutrophil to lymphocyte ratio and
the neutrophil to lymphocyte ratio predict prognosis in breast
cancer? Int J Clin Oncol. 20:70–81. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Noh H, Eomm M and Han A: Usefulness of
pretreatment neutrophil to lymphocyte ratio in predicting
disease-specific survival in breast cancer patients. J Breast
Cancer. 16:55–59. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Azab B, Shah N, Radbel J, Tan P, Bhatt V,
Vonfrolio S, Habeshy A, Picon A and Bloom S: Pretreatment
neutrophil/lymphocyte ratio is superior to platelet/lymphocyte
ratio as a predictor of long-term mortality in breast cancer
patients. Med Oncol. 30:4322013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Koh YW, Lee HJ, Ahn JH, Lee JW and Gong G:
Prognostic significance of the ratio of absolute neutrophil to
lymphocyte counts for breast cancer patients with ER/PR-positivity
and HER2-negativity in neoadjuvant setting. Tumour Biol.
35:9823–9830. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dubsky P, Sevelda P, Jakesz R,
Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B,
Steger G, Kwasny W, et al: Anemia is a significant prognostic
factor in local relapse-free survival of premenopausal primary
breast cancer patients receiving adjuvant
cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Clin
Cancer Res. 14:2082–2087. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bottini A, Berruti A, Brizzi MP, Bersiga
A, Generali D, Allevi G, Aguggini S, Bolsi G, Bonardi S, Bertoli G,
et al: Pretreatment haemoglobin levels significantly predict the
tumour response to primary chemotherapy in human breast cancer. Br
J Cancer. 89:977–982. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vaupel P, Mayer A, Briest S and Höckel M:
Hypoxia in breast cancer: Role of blood flow, oxygen diffusion
distances, and anemia in the development of oxygen depletion. Adv
Exp Med Biol. 566:333–342. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peters-Engl C, Cassik P, Schmidt I,
Denison U, Medl M, Pokieser W and Sevelda P: Impact of haemoglobin
levels during adjuvant chemotherapy on the survival of patients
with primary breast cancer. Acta Oncol. 44:129–133. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Boehm DU, Lebrecht A, Schmidt M, Siggelkow
W, Lindner C, Litz A, Ulbrich E and Koelbl H: Prognostic impact of
haemoglobin levels in breast cancer. Anticancer Res. 27:1223–1226.
2007.PubMed/NCBI
|
|
22
|
Karvellas CJ, Sawyer M, Hamilton M and
Mackey JR: Effect of capecitabine on mean corpuscular volume in
patients with metastatic breast cancer. Am J Clin Oncol.
27:364–368. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bozkurt O, Berk V, Kaplan MA, Cetin B,
Ozaslan E, Karaca H, Inanc M, Duran AO and Ozkan M: Lack of
prognostic value of mean corpuscular volume with capecitabine
therapy in metastatic breast cancer. Asian Pac J Cancer Prev.
15:2501–2504. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ludwig H, Müldür E, Endler G and Hübl W:
Prevalence of iron deficiency across different tumors and its
association with poor performance status, disease status and
anemia. Ann Oncol. 24:1886–1892. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ludwig H, Van Belle S, Barrett-Lee P,
Birgegård G, Bokemeyer C, Gascón P, Kosmidis P, Krzakowski M,
Nortier J, Olmi P, et al: The european cancer anaemia survey
(ECAS): A large, multinational, prospective survey defining the
prevalence, incidence, and treatment of anaemia in cancer patients.
Eur J Cancer. 40:2293–2306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tarocco RP, Faro G, Sargiotto A and
Ansermin A: Folate and vitamin B12 deficiency. Characterization of
parameters for early diagnosis. Recenti Prog Med. 80:547–550.
1989.(In Italian). PubMed/NCBI
|
|
27
|
Toprak B, Yalcin HZ and Colak A: Vitamin
B12 and folate deficiency: Should we use a different cutoff value
for hematologic disorders? Int J Lab Hematol. 36:409–414. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shrubsole MJ, Jin F, Dai Q, Shu XO, Potter
JD, Hebert JR, Gao YT and Zheng W: Dietary folate intake and breast
cancer risk: Results from the Shanghai breast cancer study. Cancer
Res. 61:7136–7141. 2001.PubMed/NCBI
|
|
29
|
Blount BC, Mack MM, Wehr CM, MacGregor JT,
Hiatt RA, Wang G, Wickramasinghe SN, Everson RB and Ames BN: Folate
deficiency causes uracil misincorporation into human DNA and
chromosome breakage: Implications for cancer and neuronal damage.
Proc Natl Acad Sci USA. 94:3290–3295. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang SM, Willett WC, Selhub J, Hunter DJ,
Giovannucci EL, Holmes MD, Colditz GA and Hankinson SE: Plasma
folate, vitamin B6, vitamin B12, homocysteine, and risk of breast
cancer. J Natl Cancer Inst. 95:373–380. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin J, Lee IM, Cook NR, Selhub J, Manson
JE, Buring JE and Zhang SM: Plasma folate, vitamin B-6, vitamin
B-12, and risk of breast cancer in women. Am J Clin Nutr.
87:734–743. 2008.PubMed/NCBI
|
|
32
|
Li B, Lu Y, Wang L and Zhang CX: Folate
intake and breast cancer prognosis: A meta-analysis of prospective
observational studies. Eur J Cancer Prev. 24:113–121. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Templeton AJ, McNamara MG, Šeruga B,
Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G,
Knox JJ, Tran B, et al: Prognostic role of neutrophil-to-lymphocyte
ratio in solid tumors: A systematic review and meta-analysis. J
Natl Cancer Inst. 106:dju1242014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Inanc M, Duran AO, Karaca H, Berk V,
Bozkurt O, Ozaslan E and Ozkan M: Haematologic parameters in
metastatic colorectal cancer patients treated with capecitabine
combination therapy. Asian Pac J Cancer Prev. 15:253–256. 2014.
View Article : Google Scholar : PubMed/NCBI
|
